Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 236-240

  Gammaitoni, Arnold R ^a   Davis, Matthew W ^b  

^a Medical Advisor   (United States)

^b Dermik Laboratories   (United States)

Author keywords

Lidocaine; Pharmacokinetics

Indexed keywords

LIDOCAINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN MANIFESTATION; STEADY STATE; SWEATING; VERTIGO; VOLUNTEER;

ADMINISTRATION, TOPICAL; ANESTHETICS, LOCAL; DELAYED-ACTION PREPARATIONS; EDEMA; ERYTHEMA; FEMALE; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0036159190     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A185     Document Type: Article

References (6)

1. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study
2. Recent developments in the treatment of neuropathic pain
3. Lidocaine patch; double-blind controlled study of new treatment method for postherpetic neuralgia
4. Multicenter; double-blind, vehicle-controlled trial of long-term use of lidocaine patches for postherpetic neuralgia
5. Topical lidocaine patch relieves a variety of neuropathic pain conditions: An open label study